论文部分内容阅读
目的观察聚乙二醇干扰素α-2b(佩乐能)联合利巴韦林治疗慢性丙型肝炎的临床疗效。方法 40例慢性丙型肝炎患者,随机分为治疗组(20例)和对照组(20例)。治疗组患者应用聚乙二醇干扰素α-2b治疗,对照组应用普通干扰素治疗,疗程48周。治疗后比较两组的治疗效果。结果临床治疗观察12、24、48周病毒学应答、生化学指标改善,治疗组明显优于对照组,差异均有统计学意义(P<0.05)。结论聚乙二醇干扰素α-2b联合利巴韦林治疗慢性丙型肝炎的疗效优于普通干扰素,早期病毒学应答率高,肝功能复常率高,副作用少,使用方便,值得临床推广应用。
Objective To observe the clinical efficacy of peginterferon alfa-2b and ribavirin in the treatment of chronic hepatitis C patients. Methods Forty patients with chronic hepatitis C were randomly divided into treatment group (20 cases) and control group (20 cases). Patients in the treatment group were treated with peginterferon alfa-2b, while those in the control group were treated with normal interferon for 48 weeks. After treatment, the treatment effect was compared between the two groups. Results The results of clinical treatment showed that the virological response at 12, 24 and 48 weeks was improved and the biochemical parameters were improved. The treatment group was significantly better than the control group (P <0.05). Conclusions Pegylated interferon α-2b combined with ribavirin is superior to common interferon in the treatment of chronic hepatitis C, with high early virological response rate, high rate of normalization of liver function, few side effects and convenient operation, which is worthy of clinical application Promote the application.